{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:10:56Z","timestamp":1789539056550,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T00:00:00Z","timestamp":1369180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s11060-013-1157-8","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T11:06:58Z","timestamp":1369134418000},"page":"155-164","source":"Crossref","is-referenced-by-count":25,"title":["Diphtheria toxin-based targeted toxin therapy for brain tumors"],"prefix":"10.1007","volume":"114","author":[{"given":"Yan Michael","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Vallera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,22]]},"reference":[{"issue":"3","key":"1157_CR1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.semradonc.2009.02.003","volume":"19","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN (2009) Chemotherapy for malignant gliomas. Semin Radiat Oncol 19(3):150\u2013154","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"1157_CR2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3322\/caac.20069","volume":"60","author":"EG Meir Van","year":"2010","unstructured":"Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60(3):166\u2013193","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1157_CR3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","volume":"6","author":"I Pastan","year":"2006","unstructured":"Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6(7):559\u2013565","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1157_CR4","first-page":"3402","volume":"52","author":"T Yokota","year":"1992","unstructured":"Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52(12):3402\u20133408","journal-title":"Cancer Res"},{"issue":"8","key":"1157_CR5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/jnci\/81.8.570","volume":"81","author":"RK Jain","year":"1989","unstructured":"Jain RK (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81(8):570\u2013576","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1157_CR6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1026238331739","volume":"65","author":"E Rustamzadeh","year":"2003","unstructured":"Rustamzadeh E, Li C, Doumbia S, Hall WA, Vallera DA (2003) Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol 65(1):63\u201375","journal-title":"J Neurooncol"},{"key":"1157_CR7","first-page":"139","volume":"166","author":"WA Hall","year":"2001","unstructured":"Hall WA (2001) Immunotoxin treatment of brain tumors. Methods Mol Biol 166:139\u2013154","journal-title":"Methods Mol Biol"},{"issue":"3","key":"1157_CR8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1042-3680(18)30379-6","volume":"7","author":"WA Hall","year":"1996","unstructured":"Hall WA (1996) Immunotoxin therapy. Neurosurg Clin N Am 7(3):537\u2013546","journal-title":"Neurosurg Clin N Am"},{"issue":"4","key":"1157_CR9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1086-5802(16)30480-6","volume":"39","author":"P Piascik","year":"1999","unstructured":"Piascik P (1999) FDA approves fusion protein for treatment of lymphoma. J Am Pharm Assoc (Wash) 39(4):571\u2013572","journal-title":"J Am Pharm Assoc (Wash)"},{"key":"1157_CR10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/CMAR.S5009","volume":"2","author":"F Lansigan","year":"2010","unstructured":"Lansigan F, Stearns DM, Foss F (2010) Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res 2:53\u201359","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1157_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.1992.76.1.0001","volume":"76","author":"WA Hall","year":"1992","unstructured":"Hall WA, Fodstad O (1992) Immunotoxins and central nervous system neoplasia. J Neurosurg 76(1):1\u201312","journal-title":"J Neurosurg"},{"issue":"3","key":"1157_CR12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.nurt.2009.04.004","volume":"6","author":"DS Bidros","year":"2009","unstructured":"Bidros DS, Vogelbaum MA (2009) Novel drug delivery strategies in neuro-oncology. Neurotherapeutics 6(3):539\u2013546","journal-title":"Neurotherapeutics"},{"issue":"3 Suppl","key":"1157_CR13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/1097-0142(19940801)74:3+<1006::AID-CNCR2820741506>3.0.CO;2-V","volume":"74","author":"CB Siegall","year":"1994","unstructured":"Siegall CB (1994) Targeted toxins as anticancer agents. Cancer 74(3 Suppl):1006\u20131012","journal-title":"Cancer"},{"issue":"1\u20132","key":"1157_CR14","first-page":"101","volume":"64","author":"E Rustamzadeh","year":"2003","unstructured":"Rustamzadeh E, Low WC, Vallera DA, Hall WA (2003) Immunotoxin therapy for CNS tumor. J Neurooncol 64(1\u20132):101\u2013116","journal-title":"J Neurooncol"},{"issue":"1","key":"1157_CR15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0092-8674(78)90099-5","volume":"15","author":"M Yamaizumi","year":"1978","unstructured":"Yamaizumi M, Mekada E, Uchida T, Okada Y (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15(1):245\u2013250","journal-title":"Cell"},{"issue":"1","key":"1157_CR16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/JCM.43.1.223-228.2005","volume":"43","author":"A Zoysa De","year":"2005","unstructured":"De Zoysa A, Efstratiou A, Hawkey PM (2005) Molecular characterization of diphtheria toxin repressor (dtxR) genes present in nontoxigenic Corynebacterium diphtheriae strains isolated in the United Kingdom. J Clin Microbiol 43(1):223\u2013228. doi: 10.1128\/JCM.43.1.223-228.2005","journal-title":"J Clin Microbiol"},{"issue":"6","key":"1157_CR17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3171\/jns.1987.66.6.0850","volume":"66","author":"J Zovickian","year":"1987","unstructured":"Zovickian J, Johnson VG, Youle RJ (1987) Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. J Neurosurg 66(6):850\u2013861","journal-title":"J Neurosurg"},{"issue":"17","key":"1157_CR18","doi-asserted-by":"crossref","first-page":"9068","DOI":"10.1016\/S0021-9258(19)52509-1","volume":"256","author":"K Sandvig","year":"1981","unstructured":"Sandvig K, Olsnes S (1981) Rapid entry of nicked diphtheria toxin into cells at low pH. Characterization of the entry process and effects of low pH on the toxin molecule. J Biol Chem 256(17):9068\u20139076","journal-title":"J Biol Chem"},{"issue":"6","key":"1157_CR19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0092-8674(92)90623-K","volume":"69","author":"JG Naglich","year":"1992","unstructured":"Naglich JG, Metherall JE, Russell DW, Eidels L (1992) Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 69(6):1051\u20131061","journal-title":"Cell"},{"issue":"4826","key":"1157_CR20","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1126\/science.3498987","volume":"238","author":"L Greenfield","year":"1987","unstructured":"Greenfield L, Johnson VG, Youle RJ (1987) Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238(4826):536\u2013539","journal-title":"Science"},{"key":"1157_CR21","first-page":"501","volume":"17","author":"P Boquet","year":"1977","unstructured":"Boquet P, Silverman MS, Pappenheimer AM Jr (1977) Interaction of diphtheria toxin with mammalian cell membranes. Prog Clin Biol Res 17:501\u2013509","journal-title":"Prog Clin Biol Res"},{"issue":"5","key":"1157_CR22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1006\/scbi.1995.0039","volume":"6","author":"AE Frankel","year":"1995","unstructured":"Frankel AE, Tagge EP, Willingham MC (1995) Clinical trials of targeted toxins. Semin Cancer Biol 6(5):307\u2013317","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"1157_CR23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3171\/jns.1989.70.2.0240","volume":"70","author":"VG Johnson","year":"1989","unstructured":"Johnson VG, Wrobel C, Wilson D, Zovickian J, Greenfield L, Oldfield EH, Youle R (1989) Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 70(2):240\u2013248","journal-title":"J Neurosurg"},{"key":"1157_CR24","doi-asserted-by":"crossref","unstructured":"Li YM, Hall WA (2011) Cell surface receptors in malignant glioma. Neurosurgery 69 (4):980-994; discussion 994. doi: 10.1227\/NEU.0b013e318220a672","DOI":"10.1227\/NEU.0b013e318220a672"},{"key":"1157_CR25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0065-230X(08)60028-7","volume":"44","author":"K Dano","year":"1985","unstructured":"Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139\u2013266","journal-title":"Adv Cancer Res"},{"issue":"2","key":"1157_CR26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01050419","volume":"18","author":"JS Rao","year":"1994","unstructured":"Rao JS, Steck PA, Tofilon P, Boyd D, Ali-Osman F, Stetler-Stevenson WG, Liotta LA, Sawaya R (1994) Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J Neurooncol 18(2):129\u2013138","journal-title":"J Neurooncol"},{"issue":"18","key":"1157_CR27","first-page":"4143","volume":"53","author":"S Mohanam","year":"1993","unstructured":"Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, Rao JS (1993) Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 53(18):4143\u20134147","journal-title":"Cancer Res"},{"issue":"10","key":"1157_CR28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/138945006778559139","volume":"7","author":"RJ Kreitman","year":"2006","unstructured":"Kreitman RJ, Pastan I (2006) Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 7(10):1301\u20131311","journal-title":"Curr Drug Targets"},{"issue":"14","key":"1157_CR29","first-page":"3656","volume":"54","author":"M Yamamoto","year":"1994","unstructured":"Yamamoto M, Sawaya R, Mohanam S, Bindal AK, Bruner JM, Oka K, Rao VH, Tomonaga M, Nicolson GL, Rao JS (1994) Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 54(14):3656\u20133661","journal-title":"Cancer Res"},{"issue":"2","key":"1157_CR30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF01052890","volume":"22","author":"S Mohanam","year":"1994","unstructured":"Mohanam S, Sawaya RE, Yamamoto M, Bruner JM, Nicholson GL, Rao JS (1994) Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor. J Neurooncol 22(2):153\u2013160","journal-title":"J Neurooncol"},{"issue":"2","key":"1157_CR31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ijc.22278","volume":"120","author":"E Rustamzadeh","year":"2007","unstructured":"Rustamzadeh E, Hall WA, Todhunter DA, Vallera VD, Low WC, Liu H, Panoskaltsis-Mortari A, Vallera DA (2007) Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int J Cancer 120(2):411\u2013419","journal-title":"Int J Cancer"},{"issue":"1","key":"1157_CR32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0167-5699(94)90021-3","volume":"15","author":"G Zurawski","year":"1994","unstructured":"Zurawski G, de Vries JE (1994) Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15(1):19\u201326","journal-title":"Immunol Today"},{"issue":"6417","key":"1157_CR33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/362248a0","volume":"362","author":"A Minty","year":"1993","unstructured":"Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B et al (1993) Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362(6417):248\u2013250","journal-title":"Nature"},{"issue":"6","key":"1157_CR34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s002620000110","volume":"49","author":"H Liu","year":"2000","unstructured":"Liu H, Jacobs BS, Liu J, Prayson RA, Estes ML, Barnett GH, Barna BP (2000) Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother 49(6):319\u2013324","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"1157_CR35","first-page":"1253","volume":"1","author":"W Debinski","year":"1995","unstructured":"Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK (1995) Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1(11):1253\u20131258","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1157_CR36","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/labinvest.3780336","volume":"81","author":"J Bernard","year":"2001","unstructured":"Bernard J, Treton D, Vermot-Desroches C, Boden C, Horellou P, Angevin E, Galanaud P, Wijdenes J, Richard Y (2001) Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13. Lab Invest 81(9):1223\u20131231","journal-title":"Lab Invest"},{"issue":"3","key":"1157_CR37","first-page":"481","volume":"15","author":"W Debinski","year":"1999","unstructured":"Debinski W, Gibo DM, Slagle B, Powers SK, Gillespie GY (1999) Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol 15(3):481\u2013486","journal-title":"Int J Oncol"},{"issue":"4","key":"1157_CR38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000049523","volume":"126","author":"BF Skinnider","year":"2001","unstructured":"Skinnider BF, Kapp U, Mak TW (2001) Interleukin 13: a growth factor in hodgkin lymphoma. Int Arch Allergy Immunol 126(4):267\u2013276","journal-title":"Int Arch Allergy Immunol"},{"issue":"6 Pt 1","key":"1157_CR39","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1067\/mai.2000.107604","volume":"105","author":"H Jiang","year":"2000","unstructured":"Jiang H, Harris MB, Rothman P (2000) IL-4\/IL-13 signaling beyond JAK\/STAT. J Allergy Clin Immunol 105(6 Pt 1):1063\u20131070","journal-title":"J Allergy Clin Immunol"},{"issue":"3 Pt 1","key":"1157_CR40","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/00005392-199709000-00077","volume":"158","author":"A Maini","year":"1997","unstructured":"Maini A, Hillman G, Haas GP, Wang CY, Montecillo E, Hamzavi F, Pontes JE, Leland P, Pastan I, Debinski W, Puri RK (1997) Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J Urol 158(3 Pt 1):948\u2013953","journal-title":"J Urol"},{"issue":"3","key":"1157_CR41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ygyno.2003.12.011","volume":"92","author":"D Ripley","year":"2004","unstructured":"Ripley D, Shoup B, Majewski A, Chegini N (2004) Differential expression of interleukins IL-13 and IL-15 in normal ovarian tissue and ovarian carcinomas. Gynecol Oncol 92(3):761\u2013768","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1157_CR42","first-page":"1948","volume":"8","author":"BH Joshi","year":"2002","unstructured":"Joshi BH, Kawakami K, Leland P, Puri RK (2002) Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of pseudomonas exotoxin. Clin Cancer Res 8(6):1948\u20131956","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1157_CR43","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/foc.2006.20.4.6","volume":"20","author":"T Shimamura","year":"2006","unstructured":"Shimamura T, Husain SR, Puri RK (2006) The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg Focus 20(4):E11","journal-title":"Neurosurg Focus"},{"issue":"2","key":"1157_CR44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/protein\/gzh023","volume":"17","author":"DA Todhunter","year":"2004","unstructured":"Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA (2004) A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 17(2):157\u2013164","journal-title":"Protein Eng Des Sel"},{"issue":"3","key":"1157_CR45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-005-9051-7","volume":"77","author":"E Rustamzadeh","year":"2006","unstructured":"Rustamzadeh E, Vallera DA, Todhunter DA, Low WC, Panoskaltsis-Mortari A, Hall WA (2006) Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. J Neurooncol 77(3):257\u2013266","journal-title":"J Neurooncol"},{"issue":"5","key":"1157_CR46","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/jcp.36.5.539","volume":"36","author":"KC Gatter","year":"1983","unstructured":"Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY (1983) Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 36(5):539\u2013545","journal-title":"J Clin Pathol"},{"issue":"5","key":"1157_CR47","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3171\/jns.1992.76.5.0838","volume":"76","author":"WA Hall","year":"1992","unstructured":"Hall WA, Godal A, Juell S, Fodstad O (1992) In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J Neurosurg 76(5):838\u2013844","journal-title":"J Neurosurg"},{"issue":"5927","key":"1157_CR48","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/304643a0","volume":"304","author":"R Newman","year":"1983","unstructured":"Newman R, Domingo D, Trotter J, Trowbridge I (1983) Selection and properties of a mouse L-cell transformant expressing human transferrin receptor. Nature 304(5927):643\u2013645","journal-title":"Nature"},{"key":"1157_CR49","unstructured":"Hall WA, Myklebust A, Godal A, Nesland JM, Fodstad O (1994) In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma. Neurosurgery 34 (4):649-655; discussion 655-646"},{"issue":"2","key":"1157_CR50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/0014-4827(84)90583-4","volume":"150","author":"J Lesley","year":"1984","unstructured":"Lesley J, Domingo DL, Schulte R, Trowbridge IS (1984) Effect of an anti-murine transferrin receptor-ricin A conjugate on bone marrow stem and progenitor cells treated in vitro. Exp Cell Res 150(2):400\u2013407","journal-title":"Exp Cell Res"},{"issue":"1","key":"1157_CR51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1023\/A:1026246500788","volume":"65","author":"M Weaver","year":"2003","unstructured":"Weaver M, Laske DW (2003) Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65(1):3\u201313","journal-title":"J Neurooncol"},{"issue":"1","key":"1157_CR52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.critrevonc.2010.09.001","volume":"80","author":"C Buonerba","year":"2011","unstructured":"Buonerba C, Di Lorenzo G, Marinelli A, Federico P, Palmieri G, Imbimbo M, Conti P, Peluso G, De Placido S, Sampson JH (2011) A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol 80(1):54\u201368. doi: 10.1016\/j.critrevonc.2010.09.001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"1157_CR53","first-page":"2311","volume":"5","author":"LH Pai-Scherf","year":"1999","unstructured":"Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, Pastan I (1999) Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 5(9):2311\u20132315","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1157_CR54","first-page":"673","volume":"72","author":"PM Capone","year":"1984","unstructured":"Capone PM, Papsidero LD, Chu TM (1984) Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors. J Natl Cancer Inst 72(3):673\u2013677","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1157_CR55","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jocn.2008.12.005","volume":"16","author":"HK Gan","year":"2009","unstructured":"Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16(6):748\u2013754","journal-title":"J Clin Neurosci"},{"issue":"Pt 1","key":"1157_CR56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/bj3070029","volume":"307","author":"RJ Kreitman","year":"1995","unstructured":"Kreitman RJ, Pastan I (1995) Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307(Pt 1):29\u201337","journal-title":"Biochem J"},{"issue":"7","key":"1157_CR57","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/sj.bjc.6605297","volume":"101","author":"BJ Stish","year":"2009","unstructured":"Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA (2009) Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer 101(7):1114\u20131123. doi: 10.1038\/sj.bjc.6605297","journal-title":"Br J Cancer"},{"issue":"19","key":"1157_CR58","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1158\/1078-0432.CCR-09-0696","volume":"15","author":"S Oh","year":"2009","unstructured":"Oh S, Stish BJ, Sachdev D, Chen H, Dudek AZ, Vallera DA (2009) A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res 15(19):6137\u20136147. doi: 10.1158\/1078-0432.CCR-09-0696","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1157_CR59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/138945009787354575","volume":"10","author":"WA Hall","year":"2009","unstructured":"Hall WA (2009) Convection-enhanced delivery: neurosurgical issues. Curr Drug Targets 10(2):126\u2013130","journal-title":"Curr Drug Targets"},{"key":"1157_CR60","doi-asserted-by":"crossref","unstructured":"Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase I study of final safety results. Neurosurgery 61 (5):1031-1037; discussion 1037-1038","DOI":"10.1227\/01.neu.0000303199.77370.9e"},{"issue":"3","key":"1157_CR61","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3171\/JNS-07\/09\/0568","volume":"107","author":"S Oh","year":"2007","unstructured":"Oh S, Odland R, Wilson SR, Kroeger KM, Liu C, Lowenstein PR, Castro MG, Hall WA, Ohlfest JR (2007) Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg 107(3):568\u2013577. doi: 10.3171\/JNS-07\/09\/0568","journal-title":"J Neurosurg"},{"issue":"2","key":"1157_CR62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-008-9612-7","volume":"89","author":"JJ Olson","year":"2008","unstructured":"Olson JJ, Zhang Z, Dillehay D, Stubbs J (2008) Assessment of a balloon-tipped catheter modified for intracerebral convection-enhanced delivery. J Neurooncol 89(2):159\u2013168. doi: 10.1007\/s11060-008-9612-7","journal-title":"J Neurooncol"},{"issue":"3","key":"1157_CR63","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2214\/AJR.06.0428","volume":"188","author":"JH Sampson","year":"2007","unstructured":"Sampson JH, Raghavan R, Provenzale JM, Croteau D, Reardon DA, Coleman RE, Rodriguez Ponce I, Pastan I, Puri RK, Pedain C (2007) Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol 188(3):703\u2013709. doi: 10.2214\/AJR.06.0428","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"1157_CR64","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1215\/15228517-2007-007","volume":"9","author":"JH Sampson","year":"2007","unstructured":"Sampson JH, Raghavan R, Brady ML, Provenzale JM, Herndon JE 2nd, Croteau D, Friedman AH, Reardon DA, Coleman RE, Wong T, Bigner DD, Pastan I, Rodriguez-Ponce MI, Tanner P, Puri R, Pedain C (2007) Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 9(3):343\u2013353. doi: 10.1215\/15228517-2007-007","journal-title":"Neuro Oncol"},{"issue":"8","key":"1157_CR65","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/neuonc\/nop054","volume":"12","author":"S Kunwar","year":"2010","unstructured":"Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK (2010) Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12(8):871\u2013881. doi: 10.1093\/neuonc\/nop054","journal-title":"Neuro Oncol"},{"issue":"1","key":"1157_CR66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1023\/A:1026294416718","volume":"65","author":"M Kawakami","year":"2003","unstructured":"Kawakami M, Kawakami K, Puri RK (2003) Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol 65(1):15\u201325","journal-title":"J Neurooncol"},{"issue":"1\u20132","key":"1157_CR67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/B:NEON.0000013478.27604.01","volume":"66","author":"NG Rainov","year":"2004","unstructured":"Rainov NG, Heidecke V (2004) Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001). J Neurooncol 66(1\u20132):197\u2013201","journal-title":"J Neurooncol"},{"issue":"6","key":"1157_CR68","first-page":"2157","volume":"6","author":"RW Rand","year":"2000","unstructured":"Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK (2000) Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6(6):2157\u20132165","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1157_CR69","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2006.08.1117","volume":"25","author":"S Kunwar","year":"2007","unstructured":"Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the cintredekin besudotox intraparenchymal study group. J Clin Oncol 25(7):837\u2013844","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-013-1157-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1157-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T13:47:21Z","timestamp":1645105641000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-013-1157-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,22]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1007\/s11060-013-1157-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,22]]}}}